尽管抗感染治疗和疫苗的开发有了新的进展,但细菌性脑膜炎仍是儿科患者主要的死亡原因。新型耐药菌株的出现,地塞米松辅助治疗疗效尚存争论,经济状况对疫苗技术推广的制约,都对儿童细菌性脑膜炎的治疗提出了新的挑战。 Despite new advances in anti-infective therapy and vaccine development, bacterial meningitis remains the major cause of death in pediatric patients. The emergence of new drug-resistant strains, the adjuvant treatment of dexamethasone is still controversial effect, the economic constraints of the vaccine technology to promote the treatment of bacterial meningitis in children poses new challenges.